A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/15 (2006.01) A61K 35/76 (2006.01)
Patent
CA 2411397
Methods for treating proliferative disorders, by administering reovirus to a ral-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts target cancer cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), other serotypes or strains of reovirus, and recombinant reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
Lee Patrick W. K.
Norman Kara L.
Oncolytics Biotech Inc.
Torys Llp
LandOfFree
Reovirus for the treatment of ral-mediated cellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reovirus for the treatment of ral-mediated cellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus for the treatment of ral-mediated cellular... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1524353